Dr. Barry Gause received his Doctor of Medicine degree from Michigan State University’s College of Human Medicine in 1976. He trained in Internal Medicine and Pediatrics at Emory University in Atlanta, Georgia followed by a 4-year fellowship in Medical Oncology at the National Cancer Institute. After completing his postdoctoral training, Gause was a faculty member at the Howard University Cancer Center where he attained the position of Chief of Medical Oncology before returning to the National Cancer Institute. During his tenure at the institute, he made contributions in therapeutic vaccines for lymphoma, melanoma, cervical, and ovarian cancer, in addition to being a senior staff member on the Lymphoma Service and the Director of the Medical Oncology Fellowship program. After a 22-year career with the National Cancer Institute, Gause joined SAIC-Frederick, Inc. (renamed Leidos Biomedical Research, Inc. in September 2013) in November of 2006 as the inaugural Director of the Clinical Research Program Directorate. This program provides regulatory, clinical trials and project management support to clinical trial programs within National Cancer Institute and National Institute of Allergy and Infectious Disease, and affords quality assurance management to the Vaccine Pilot Plant and the Biopharmaceutical Development Programs of the Frederick National Laboratory. He has continued as a member of the Medical Oncology Branch providing clinical care for patients on the Lymphoma Service in the inpatient and outpatient setting.
In September 2008, Gause was appointed as the Chief Medical Officer. This group consists of 4 directorates; Biopharmaceutical Development Program, Applied and Developmental Research, Vaccine Clinical Materials Program, and the Clinical Research Program. This provides synergy and collaboration between those Frederick National Laboratory directorates at the clinical end of the translational research spectrum.
